University Hospitals' Deepgen HIV assay will use Advanced Biological Laboratories' DeepChek software to help monitor drug resistance and minority variants in HIV strains.
The real-time PCR assay is designed to detect and identify HIV, hepatitis B virus, and hepatitis C virus in donations of human whole blood and blood components.
Shipping of the assay, Cepheid's eighth product release in 2014, is anticipated to begin in February 2015.
With the precision of PCR, the method could ultimately be used to build faster, simpler diagnostics.
The new claims allow for pre-transplantation testing of organ and tissue donations for HIV, hepatitis B virus, hepatitis C virus, and West Nile virus.
The platform — called NINA for non-instrumented nucleic acid amplification — is designed to work with a wide range of isothermal amplification methods.
Roche today said that its Cobas HIV-1 and HCV next-generation viral load monitoring assays have received CE marking.
The firm said the product is the first HIV viral load assay with a dual claim for diagnosis and treatment monitoring.
MOgene, a genomics services provider, launched a new subsidiary this week called MOgene Clinical Diagnostics (MOgeneDx) to provide next-generation sequencing-based testing for infectious diseases and immune disorders.
Two new studies demonstrate improved methods using droplet digital PCR to detect very low viral loads in HIV-positive patients, pushing the detection threshold lower than that of real-time PCR.
A Harvard University professor has been charged with making false claims regarding funds he received from China, the New York Times reports.
Discover magazine reports that animal dissections might dissuade students from science careers, but that a firm has developed synthetic frogs for dissections.
Nature News reports that a US panel is reviewing current guidelines for federally funded gain-of-function viral research.
In PNAS this week: de novo mutation patterns among the Amish, an alternative RNA-seq method, and more.